Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Drug Device Combination Market Worth $177.7 Billion by 2024: Grand View Research, Inc.


News provided by

Grand View Research, Inc.

05 Oct, 2016, 09:15 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Grand View Research Logo (PRNewsFoto/Grand View Research_ Inc_)

SAN FRANCISCO, October 5, 2016 /PRNewswire/ --

The drug device combination market is expected to reach USD 177.7 billion by 2024, according to a new study by Grand View Research, Inc. The drug device combination market is primarily driven by exponential growth in the production of advanced drug delivery devices coupled with the growing chronic disease burden, which is anticipated to be one of the primary factors to accelerate the overall demand of the market throughout the forecast period. The unprecedented adoption rate of these products is also believed to be a consequence of its inherent benefits over the traditional pharmacological alternatives to deliver therapeutics, which in turn influences pharmaceutical, biotechnology, and medical device companies to work toward further developing these products for subsequent commercialization.

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757 )

As a consequence of the high patient and physician demand, it is observed that regulatory agencies have developed specific competencies and regulations for combination product manufacturers. The regulatory healthcare agencies across the globe, notably the Pharmaceuticals Medical Devices Agency, Japan and the U.S. FDA, require manufacturers to gain deep insights pertaining to specific patient requirements in numerous countries to ensure accurate and timely market access to the drug device combination products. In addition, these regulatory bodies ensure the development of sophisticated combination products for enhanced drug delivery with a high safety level. Such heightening sophistication in the overall manufacturing process is believed to accentuate the demand for combination products and encourage high participation by the pharmaceutical and medical device companies.

Browse full research report with TOC on "Drug Device Combination Market Analysis By Product (Infusion Pumps, Volumetric, Disposable, Syringe, Ambulatory, Implantable, Insulin, Orthopedic Combination Products, Bone Graft Implants, Antibiotic Bone Cement, Photodynamic Therapy Devices, Coronary Stents, Peripheral Vascular Stents, Transdermal Patches, Drug Eluting Stents, Wound Care Products, Inhalers, Dry Powder, Nebulizers, Metered Dose, Antimicrobial Catheters, Urological, Cardiovascular), And Segment Forecasts To 2024" at: http://www.grandviewresearch.com/industry-analysis/drug-device-combination-market

Further Key Findings From the Study Suggest: 

  • Segment with transdermal patches held the dominant share of over 35.0% in the product segment in 2015. The substantial share can be attributed to the consistent technological advancements that present this drug delivery mode with benefits over conventional treatment methods. 
  • Inclusion of third-generation iontophoresis and microneedle technology, matrix-controlled transdermal systems, and thermo effectors in transdermal patches are some of technological innovations contributing toward the segment share
  • Inhalers are anticipated to grow at a profitable rate throughout the forecast period owing to the rising prevalence of asthma and COPD coupled with the surging awareness of innovative therapies including controlled or programmable drug dosing
  • Thenebulizers are expected to grow at a lucrative rate during the forecast period owing to easy drug administration with active pharmaceutical ingredients delivered in the form of fine mist. This facilitates direct delivery of therapeutics to the lungs, which proves to be the most convenient way of providing medication to infants and toddlers, thereby propelling the demand for nebulizers during the forecast period.
  • In 2015, North America dominated the regional drug device combination vertical with a share of over 42.0%. The dominant share is a consequence of high investment in the R&D sector of advanced drug delivery technologies, the resultant technological advances in this space, and the subsequent high adoption of innovative combination products owing to convincing therapeutic outcomes.
  • Asia Pacific is expected to witness growth at an exponential CAGR during the forecast period. The exponential growth rate is attributed to the increasing healthcare spending, improving infrastructure quality pertaining to drug development and discovery, increasing outsourcing manufacturing activities, and the adoption of compact and low cost techniques.
  • The key players are consistently employing new product development and collaborative strategies to attain a higher share and gain a competitive advantage in the sector. For instance, in August 2016, W.L. Gore & Associates, Inc. announced the FDA approval of its dual-component stent, GORE TIGRIS vascular stent with a fluoropolymer/nitinol design.
  • The aforementioned product launch was carried out to expand options for the treatment of peripheral artery disease, which allows easy insertion and better clinical outcomes, even in a challenging anatomy

Grand View Research has segmented the drug device combination market on the basis of product and region: 

  • Global Drug Device Combination Product Outlook (Revenue, USD Billion, 2013 - 2024) 
    • Infusion Pumps
      • Volumetric
      • Disposables
      • Syringes
      • Ambulatory
      • Implantables
      • Insulin
    • Orthopedic Combination Products
      • Bone Graft Implants
      • Antibiotic Bone Cement
    • Photodynamic Therapy Devices
    • Transdermal Patches
    • Drug Eluting Stents
      • Coronary stents
      • Peripheral vascular stents
    • Wound Care Products
    • Inhalers
      • Dry powder
      • Nebulizers
      • Metered dose
    • Antimicrobial Catheters
      • Urological
      • Cardiovascular
      • Others
    • Others
  • Drug Device Combination Regional Outlook (Revenue, USD Billion, 2013 - 2024) 
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Mexico
      • Brazil
    • MEA
      • South Africa

Browse related reports by Grand View Research: 

  • Theranostics Market - http://www.grandviewresearch.com/industry-analysis/theranostics-market
  • Coagulation Analyzers Market - http://www.grandviewresearch.com/industry-analysis/coagulation-analyzers-market
  • Hospital Microbiology Testing Market - http://www.grandviewresearch.com/industry-analysis/hospital-microbiology-testing-market
  • Angioplasty Balloons Market - http://www.grandviewresearch.com/industry-analysis/angioplasty-balloons-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs - legalworkshop.org, grandviewresearch.com/blogs/healthcare


Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com

Modal title

Also from this source

Vineet Agarwal Joins Grand View Research as Investor and Board Member

Vineet Agarwal Joins Grand View Research as Investor and Board Member

We are pleased to announce that Vineet Agarwal, a seasoned business leader and investor with over 20 years of experience in strategy, research &...

Grand View Research's Latest Market Research Findings Predict Major Shifts in Flooring Market by 2030

Grand View Research's Latest Market Research Findings Predict Major Shifts in Flooring Market by 2030

The global flooring market size is estimated to reach USD 534.6 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.